3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
685
Cholangiocarcinoma
113
Biliary Tract Neoplasms
95
Neoplasms
69
Neoplasm Metastasis
66
Gallbladder Neoplasms
61
Colorectal Neoplasms
49
Bile Duct Neoplasms
40
Carcinoma, Non-Small-Cell Lung
37
Adenocarcinoma
28
Carcinoma, Hepatocellular
26
Stomach Neoplasms
22
Liver Neoplasms
21
Colonic Neoplasms
21
Ovarian Neoplasms
20
Lung Neoplasms
19
Breast Neoplasms
18
Rectal Neoplasms
15
Carcinoma, Pancreatic Ductal
15
Pancreatic Adenocarcinoma
13
Esophageal Neoplasms
13
Sarcoma
12
Carcinoma
11
Small Cell Lung Carcinoma
10
Urinary Bladder Neoplasms
9
Gastrointestinal Neoplasms
9
Advanced Pancreatic Cancer
9
Triple Negative Breast Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Interventions
ganitumab
1
Surgical Procedures, Operative
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Jaundice
×
Gemcitabine
×
Gastrointestinal
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts